INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO, Calif. & CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- NantKwest, Inc.
View HTML
Toggle Summary Cord Blood Registry (CBR®) by Generate Life Sciences Partners With NantKwest to Develop COVID-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest
View HTML
Toggle Summary ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory.  Inclusion of nucleocapsid in this vaccine construct potentially
View HTML
Toggle Summary Engineered Killer Immune Cells Target Tumours and Their Immunosuppressive Allies View HTML
Toggle Summary NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 29, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock
View HTML
Toggle Summary NantKwest Announces Pricing of Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price
View HTML
Toggle Summary NantKwest Announces Proposed Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public
View HTML
Toggle Summary NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
 NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK cells, haNK cells engineered
View HTML
Toggle Summary ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting humoral and
View HTML
Toggle Summary NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
EL SEGUNDO, Calif. ,--(BUSINESS WIRE)--May 26, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET .
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.